Key takeaways:

In patients with chronic HFrEF, vericiguat reduced risk for death but not heart failure hospitalization.

In a meta-analysis of patients with chronic or worsening HFrEF, vericiguat showed consistent benefit.

Perspective from Deepak L. Bhatt, MD, MPH

In patients with chronic HF with reduced ejection fraction, vericiguat reduced risk for all-cause and CV death but not HF hospitalization compared with placebo, according to results of the VICTOR trial.

However, in a meta-analysis of VICTOR and the previously reported VICTORIA trial of vericiguat in patients with worsening HFrEF , vericiguat (Verquvo, Merck/Bayer), an oral soluble guanylate cyclase stimulator, was linked with reduced risk for CV death and HF hospitalization compared with placebo. The trial and meta-analysi

See Full Page